Nuclear PLD1 combined with NPM1 induces gemcitabine resistance through tumorigenic IL7R in pancreatic adenocarcinoma.
Danqi FuJingrui YanZhaoyu ZhangYang LiuXiaoqing MaJinsheng DingShengyu YangRan ZhaoAntao ChangChuntao GaoJing LiuTiansuo ZhaoXiuchao WangChongbiao HuangSong GaoYing MaBo TangYukuan FengHongwei WangBaocun SunPublished in: Cancer biology & medicine (2023)
PLD1 is an enzyme that has a critical role in PDAC-associated gemcitabine resistance through a non-enzymatic interaction with NPM1, further promoting the downstream JAK1/STAT5/Bcl-2 pathway. Inhibiting any of the participants of this pathway can increase gemcitabine sensitivity.